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Characteristics of men responding to an
invitation to undergo testing for prostate
cancer as part of a randomised trial
Eleanor I. Walsh1*, Emma L. Turner1, J. Athene Lane1, Jenny L. Donovan1, David E. Neal2, Freddie C. Hamdy2,
Richard M. Martin1, and the CAP & ProtecT Trial Groups
Abstract
Background: Sociodemographic characteristics are associated with participating in cancer screening and trials.
We compared the characteristics of those responding with those not responding to a single invitation for
prostate-specific antigen (PSA) testing for prostate cancer as part of the Cluster randomised triAl of PSA testing
for Prostate cancer (CAP).
Methods: Age, rurality and deprivation among 197,763 men from 271 cluster-randomised primary care centres in
the UK were compared between those responding (n = 90,300) and those not responding (n = 100,953) to a prostate
cancer testing invitation.
Results: There was little difference in age between responders and nonresponders. Responders were slightly more
likely to come from urban rather than rural areas and were slightly less deprived than those who did not respond.
Conclusion: These data indicate similarities in age and only minor differences in deprivation and urban location
between responders and nonresponders. These differences were smaller, but in the same direction as those observed
in other screening trials.
Trial registration: ISRCTN92187251. Registered on 29 November 2004.
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Background
Screening for prostate cancer (PCa) has been shown to
reduce disease-specific morbidity and mortality through
early detection, but at the expense of overdiagnosis and
overtreatment of indolent cancer [1–3]. The UK National
Screening Committee (UKNSC) does not currently rec-
ommend population screening for PCa, although testing
can be performed on request [4]. The UKNSC awaits the
results of ongoing nationwide trials to further inform UK
PCa screening policy. The Cluster randomised triAl of
PSA testing for Prostate cancer (CAP) is an effectiveness
trial comparing PCa-specific mortality in men invited
(intervention arm) and men not invited (control arm) to
prostate-specific antigen (PSA) testing in primary care [5]
and the Prostate testing for cancer and treatment
(ProtecT) randomised controlled trial (RCT), which
evaluates the effectiveness and cost-effectiveness of
treatment for localised, PSA-detected PCa [6].
Material and social deprivation is associated with
lower rates of attending cancer screening programmes
for both men [7–9] and women [10–14], as well as RCT
participation [15]. Failure to enroll participants who are
representative of the target population can compromise
the generalisability of trial findings [16], for example,
due to a healthy volunteer effect (HVE) [17] with youn-
ger, healthier, more-educated individuals taking part
compared with nonattendees [18]. Here we compare the
characteristics of those who responded to the invitation
to take part in the intervention arm of the CAP trial
with those who did not, using routine data available
from primary care centres.
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Methods
Men aged 50–69 years from 271 primary care (GP) prac-
tices in England and Wales were cluster-randomised to
receive the intervention in the CAP trial (Fig. 1) of a
postal invitation to attend a one-off appointment for a
PSA test screening for PCa. Those who returned a reply
slip by post accepting this invitation (i.e. ‘responders’)
were given an appointment and invited to participate in
the screening and diagnostic stage of the ProtecT trial
[6]. Responders who were ineligible or decided not to
participate in the ProtecT study were followed up as part
of the CAP trial (discussed in full elsewhere; [5]). Those
who declined the initial invitation (i.e ‘nonresponders’)
were also followed up as part of the CAP trial [5].
Data
Date of birth and postcode were provided by the pri-
mary care practices for all men who were invited to
screening for recruitment purposes. These are the only
demographic data items available for both responders
and nonresponders due to governance and ethical per-
missions. Postcode was used to calculate the Index
Multiple Deprivation (IMD) score and the Rural and
Urban Area Classification (RUAC).
Index Multiple Deprivation (IMD)
The IMD is a widely used measure of area deprivation in
England and Wales and has been shown to represent
deprivation appropriately for both urban and rural areas
[19]. The IMD is an overall composite score of weighted
domains with higher scores indicating more deprivation
encompassing aspects of socioeconomic status including
unemployment, claiming financial support from the
state, poor health, low educational attainment, criminal
victimisation, household condition and overcrowding.
English 2004 and Welsh 2005 IMD scores are not directly
comparable and are, therefore, analysed separately [20].
Rural and Urban Area Classification (RUAC)
The RUAC (2004) is a measure of population density
and sparseness in the UK. For RUAC, areas of more than
10,000 people are considered to be urban, otherwise they
are classified as rural (i.e. less than 10,000 people).
Statistical analysis
A t test was used to compare mean age and deprivation
in responders and nonresponders. Odds ratios (ORs)
were used to compare the proportion of responders and
nonresponders living in an urban location. Gartner et al.
[19] found that deprivation accounted for the differences
they found in outcomes by urban-rural location, and we
therefore adjusted this analysis by IMD score. Analyses
were conducted in STATA version 13.
Results
Of 197,763 men registered at primary care practices who
were randomised to receive invitations to the PSA
testing clinic, 46 % (n = 90,300) accepted the invitation
(responders) and 51 % did not respond (n = 100,953;
i.e. nonresponders). The remaining men either explicitly
refused the invitation (1.5 %; n = 3,010) or, having
attended, refused to take part in the trial (1.8 %; n = 3,499).
Eighty-four percent (n = 75,753) of responders ultimately
attended the clinic, of which 98 % (n = 65,836) reported
themselves as being of White ethnic origin.
The mean age of both responders and nonresponders
was 59 years (5.47 and 5.66 standard deviations (SDs),
respectively; see Table 1). Responders in England and
Wales were less deprived on average compared to non-
responders (IMD 20.66 (SD 15.49) versus 25.04 (SD
Fig. 1 Trial and follow-up organisation
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17.74); p < 0.001 and 19.04 (SD 14.08) versus 22.27 (SD
15.28); p < 0.001, respectively). The distribution of IMD
scores between responders and nonresponders are com-
parable (see Fig. 2a and b), as demonstrated by the inter-
quartile range (IQR) of both IMD scores in England
(responders’ IQR 9.3–28.5 versus nonresponders’ IQR
10.9–37.2) and Wales (responders’ IQR 8.2–26.9 versus
nonresponders’ IQR 10.3–31.8).
Responders were also slightly less likely to live in
urban areas with a population of more than 10,000 than
nonresponders (85 % [95 % confidence interval (CI) 0.85
to 0.86] versus 87 % [95 % CI 0.87 to 0.87]; p < 0.001),
and slightly more likely to be from urban locations when
controlling for deprivation, in both England (crude OR
0.85, 95 % CI 0.83 to 0.87 compared with adjusted OR
1.04, 95 % CI 0.99 to 1.09) and Wales (crude OR 1.01,
95 % CI 0.91 to 1.13 compared with adjusted OR 1.11,
95 % CI 0.95 to 1.30).
There was no difference in the results when classifying
those who accepted the invitation, but did not ultimately
attend the clinic or undergo a PSA test (n = 22,964), as
nonresponders rather than responders.
Discussion
There were very small differences between those who
responded and those who did not respond to a single in-
vitation to receive a PSA test as the intervention in the
CAP trial. Responders and nonresponders were similar
in age. Responders were only slightly less deprived than the
nonresponders, and there were negligible differences in
urban-rural location. Although we report small p values,
these reflect the large numbers in the study as the absolute
differences are very small in magnitude.
Table 1 Demographics of responders and nonresponders to screening invitation
Nonresponders Responders p value for difference
n = 100,953 n = 90,300
Age at randomisation (SD) 58.9 (5.66) 59.1 (5.47) < 0.0001a
N 100,953 90,285
Mean England Index of Multiple Deprivation (IMD) score (SD) 25.04 (17.74) 20.66 (15.49) < 0.0001a
N 85,521 78,882
Mean Wales Index of Multiple Deprivation (IMD) score (SD) 22.27 (15.28) 19.04 (14.08) < 0.0001a
N 15,432 11,418
Urban (>10,000 people)
England and Wales combined % OR (95 % CI) 87 % (baseline) 85 % < 0.0001c
0.84 (0.82–0.86)
England % (OR; 95 % CI) 86 % (baseline) 84 % (0.85; 0.83–0.87) < 0.0001c
[adjusted OR; 95 % CI; p value]b [1.04; 0.99–1.09] [0.14]c
Wales % (OR; 95 % CI) 95 % (baseline) 95 % (1.01; 0.91–1.13) 0.83
[adjusted OR; 95 % CI; p value]b [1.11; 0.95–1.30] [0.19]c
at test, bEnglish and Welsh IMD scores are adjusted for separately because they are derived differently and should not be combined, cLogistic regression
CI confidence interval, OR odds ratio
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Fig. 2 a Frequency distribution of Welsh Index Multiple Deprivation
(IMD) scores for those responding (solid line) to a one-off invite to a
PSA test compared to those who did not respond (dash) to this
invitation. b Frequency distribution of English IMD scores for those
responding (solid line) to a one-off invite to a PSA test compared
to those who did not respond (dash) to this invitation
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The CAP trial gained consent after randomisation to
receive or not receive an invitation to screening and, by
analysing on this intention-to-screen basis, reduces the
risk of self-selection bias influencing the representative-
ness to the target population. This is compared to other
trials where consent was gained prior to randomisation
[21]. However, differences between men who did and
did not actually undergo a PSA test is a key issue for
policy-makers and cannot be ruled out as having an im-
pact on the effectiveness of screening.
It was only possible to derive age, urban/rural location
and an ecological measure of deprivation from the avail-
able data because of ethical and governance regulations.
The large randomly allocated cohort and intention-to-
screen analysis in the CAP trial helps to mitigate the effect
of unmeasured factors on generalisability of the trial.
While the responders and nonresponders were similar ac-
cording to the characteristics measured, it cannot be ruled
out that there were other differences between the groups.
Important differences in comorbidities, education, income
and decision-making between attendees and nonattendees
have been shown elsewhere [32, 33] and remain key
factors for policy-makers.
We are unable to comment on the impact of any post-
randomisation differences between the groups on mor-
tality and PCa incidence. Previous trials have suggested
that nonparticipation in the screening arm is associated
with higher mortality [22] and that controlling for
‘healthier’ attenders in the screening arm is important to
avoid overestimating the effect of screening on mortality
[18]. This is something that could be investigated in the
future once the median 10-year intention-to-screen ana-
lyses have been reported.
This RCT invited over 190,000 patients to attend a
one-off blood test from different geographical regions
across the UK. According to these characteristics, those
who responded to the invitation were representative of
the population who were invited as a whole and compar-
able with those enrolled in other screening trials [23, 24].
Compared to other PCa screening trials, considerably
more men were invited in this trial and overall response
rates were studied [6]. Other trials have not consistently
reported the numbers initially invited (cf. [25–31]) or have
reported on a sample of participant uptake of invitations
to testing prior to publication of the primary analysis [21].
Group-level data (i.e. postcode) limits the sensitivity of
deprivation data at an individual level, and area measures
of deprivation are an average of the overall deprivation of
the population, which arguably cannot represent the level
of deprivation in the age- and gender-specific group in-
cluded in this trial [34]. Further, without ethnicity infor-
mation for all those invited we cannot investigate the lack
of ethnic diversity among attenders (more than 90 % of
whom are of White ethnicity). Although, this figure does
reflect the 2001 UK Census, which reported that 89 % and
97 % of English and Welsh residents, respectively, from
urban areas were classified as of ‘White’ ethnicity [35].
Despite changes in the most recent Consolidated Stan-
dards of Reporting Trials (CONSORT) guidelines, there
are very few trials that report the figures required to assess
the impact of trial participation on health outcomes and
survival [36]. It is difficult to assess who is likely to attend
screening if trials do not publish prerecruitment figures
and the details of those who are being enrolled remain
under-reported [37, 38]. Without adequate reporting of the
groups who do and do not participate potential external
validity and barriers to screening and treatment cannot be
properly assessed. Describing the characteristics of those
enrolled and those not enrolled in trials, to ascertain the
generalisability of the trial results and to assess the validity
of the recruited sample, has been recommended [39].
Conclusions
We have reported key characteristics that describe those
who did and those who did not respond to a single invi-
tation to undergo a PSA test in the ProtecT and CAP
RCTs. Overall, there were only minor differences in
area-deprivation measures and urban-rural location be-
tween those who responded and did not respond to the
invitation. Therefore, this is unlikely to affect the general-
isability of the ProtecT and CAP trials. Despite restricted
access to routine data limiting the comparisons that could
be made between responders and nonresponders, this ana-
lysis suggests that those who are likely to engage with
screening do not differ from those who would not in a
meaningful way. Moreover, the characteristics of those
who responded are comparable to those observed in other
screening trials and add to knowledge about who might
accept an invitation to PCa screening, if a programme
were to be initiated in England and Wales.
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